James M Wilson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7003539/publications.pdf

Version: 2024-02-01

623	62,064	435 131	1424 221
papers	citations	h-index	g-index

642	642	642	30960
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A. Human Gene Therapy, 2022, 33, 421-431.	2.7	2
2	Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression. Molecular Therapy - Methods and Clinical Development, 2022, 24, 292-305.	4.1	10
3	Efficacy and Safety of a Krabbe Disease Gene Therapy. Human Gene Therapy, 2022, 33, 499-517.	2.7	24
4	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy, 2022, 30, 2952-2967.	8.2	2
5	Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. Biomaterials Science, 2021, 9, 1449-1463.	5.4	84
6	Increasing the Specificity of AAV-Based Gene Editing through Self-Targeting and Short-Promoter Strategies. Molecular Therapy, 2021, 29, 1047-1056.	8.2	11
7	CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	31
8	Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device. Nano Letters, 2021, 21, 5671-5680.	9.1	120
9	Long-term stable reduction of low-density lipoprotein in nonhuman primates following inÂvivo genome editing of PCSK9. Molecular Therapy, 2021, 29, 2019-2029.	8.2	42
10	Intranasal gene therapy to prevent infection by SARS-CoV-2 variants. PLoS Pathogens, 2021, 17, e1009544.	4.7	36
11	Isolating Natural Adeno-Associated Viruses from Primate Tissues with a High-Fidelity Polymerase. Human Gene Therapy, 2021, 32, 1439-1449.	2.7	3
12	Adeno-Associated Virus Vector-Mediated Expression of Antirespiratory Syncytial Virus Antibody Prevents Infection in Mouse Airways. Human Gene Therapy, 2021, , .	2.7	4
13	Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model. Molecular Genetics and Metabolism, 2021, 134, 139-146.	1.1	6
14	Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia. Molecular Therapy - Methods and Clinical Development, 2021, 22, 1-10.	4.1	14
15	Context-Specific Function of the Engineered Peptide Domain of PHP.B. Journal of Virology, 2021, 95, e0116421.	3.4	13
16	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host and Microbe, 2021, 29, 1437-1453.e8.	11.0	53
17	A Single Injection of an Optimized Adeno-Associated Viral Vector into Cerebrospinal Fluid Corrects Neurological Disease in a Murine Model of GM1 Gangliosidosis. Human Gene Therapy, 2020, 31, 1169-1177.	2.7	22
18	Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration. Molecular Therapy - Methods and Clinical Development, 2020, 17, 969-974.	4.1	26

#	Article	IF	Citations
19	MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Science Translational Medicine, 2020, 12, .	12.4	96
20	Moving Forward after Two Deaths in a Gene Therapy Trial of Myotubular Myopathy. Genetic Engineering and Biotechnology News, 2020, 40, 14, 16.	0.1	1
21	Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology. Human Gene Therapy, 2020, 31, 808-818.	2.7	129
22	Adenoâ€associated virus serotype 1â€based gene therapy for FTD caused by GRN mutations. Annals of Clinical and Translational Neurology, 2020, 7, 1843-1853.	3.7	26
23	Sensitive Determination of Infectious Titer of Recombinant Adeno-Associated Viruses (rAAVs) Using TCID₅₀ End-Point Dilution and Quantitative Polymerase Chain Reaction (qPCR). Cold Spring Harbor Protocols, 2020, 2020, pdb.prot095653.	0.3	5
24	ITR-Seq, a next-generation sequencing assay, identifies genome-wide DNA editing sites in vivo following adeno-associated viral vector-mediated genome editing. BMC Genomics, 2020, 21, 239.	2.8	35
25	Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy. Human Gene Therapy, 2020, 31, 695-696.	2.7	145
26	Isolating Human Monoclonal Antibodies Against Adeno-Associated Virus From Donors With Pre-existing Immunity. Frontiers in Immunology, 2020, 11, 1135.	4.8	7
27	Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial. Molecular Therapy, 2020, 28, 784-793.	8.2	35
28	A mutation-independent CRISPR-Cas9â€“mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. Science Advances, 2020, 6, eaax5701.	10.3	44
29	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. Frontiers in Immunology, 2020, 11, 626464.	4.8	4
30	Cycling at the Frontiers of Gene Therapy. Human Gene Therapy Clinical Development, 2019, 30, 47-49.	3.1	1
31	Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. Journal of Controlled Release, 2019, 316, 404-417.	9.9	111
32	TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy. Cellular Immunology, 2019, 346, 103997.	3.0	33
33	A Birds-Eye View: An Interview with Nick Leschly. Human Gene Therapy Clinical Development, 2019, 30, 5-6.	3.1	0
34	Breakthrough to Bedside: Bringing Gene Therapy to Neuromuscular Diseases: An Interview with Dr. Jerry R. Mendell. Human Gene Therapy Clinical Development, 2019, 30, 93-96.	3.1	1
35	A Gene Therapy Approach to Improve Copper Metabolism and Prevent Liver Damage in a Mouse Model of Wilson Disease. Human Gene Therapy Clinical Development, 2019, 30, 29-39.	3.1	14
36	Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys. Human Gene Therapy, 2019, 30, 957-966.	2.7	60

#	Article	IF	Citations
37	The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. Molecular Therapy, 2019, 27, 912-921.	8.2	158
38	CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IXâ€“knockout mice. Blood, 2019, 133, 2745-2752.	1.4	57
39	Adeno-associated virus-mediated expression of human butyrylcholinesterase to treat organophosphate poisoning. PLoS ONE, 2019, 14, e0225188.	2.5	5
40	Susceptibility to SIV Infection After Adenoviral Vaccination in a Low Dose Rhesus Macaque Challenge Model. Pathogens and Immunity, 2019, 4, 1.	3.1	3
41	Interview with Jean Bennett, MD, PhD. Human Gene Therapy Clinical Development, 2018, 29, 7-9.	3.1	3
42	Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors. Human Gene Therapy Methods, 2018, 29, 86-95.	2.1	46
43	AAV8 Gene Therapy Rescues the Newborn Phenotype of a Mouse Model of Criglerâ€“Najjar. Human Gene Therapy, 2018, 29, 763-770.	2.7	19
44	The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Molecular Therapy, 2018, 26, 664-668.	8.2	300
45	Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Human Gene Therapy, 2018, 29, 285-298.	2.7	543
46	AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. Molecular Therapy, 2018, 26, 542-549.	8.2	36
47	Lancet Commission: Stem cells and regenerative medicine. Lancet, The, 2018, 391, 883-910.	13.7	184
48	Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. Human Gene Therapy, 2018, 29, 15-24.	2.7	92
49	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. Journal of Virology, 2018, 92, .	3.4	24
50	Tachi Yamada: An Academic, Drug Developer and Humanist. Human Gene Therapy Clinical Development, 2018, 29, 176-178.	3.1	0
51	AAV8 Gene Therapy for Crigler-Najjar Syndrome in Macaques Elicited Transgene T Cell Responses That Are Resident to the Liver. Molecular Therapy - Methods and Clinical Development, 2018, 11, 191-201.	4.1	14
52	Gene Therapy Entering the Land of Oz. Human Gene Therapy Clinical Development, 2018, 29, 171-171.	3.1	0
53	University Flunk-Out to Genomics Pioneer: An Interview with George Church, PhD. Human Gene Therapy Clinical Development, 2018, 29, 118-120.	3.1	0
54	The RAC Retires After a Job Well Done. Human Gene Therapy Clinical Development, 2018, 29, 115-117.	3.1	0

#	Article	IF	Citations
55	Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science, 2018, 362, 598-602.	12.6	170
56	Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function. Molecular Therapy, 2018, 26, 2848-2862.	8.2	68
57	Adeno-associated viral gene therapy corrects a mouse model of argininosuccinic aciduria. Molecular Genetics and Metabolism, 2018, 125, 241-250.	1.1	16
58	Accurate and Rapid Sequence Analysis of Adeno-Associated Virus Plasmids by Illumina Next-Generation Sequencing. Human Gene Therapy Methods, 2018, 29, 201-211.	2.1	6
59	Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. Cancer Research, 2018, 78, 6171-6182.	0.9	15
60	Preparation of Nonhuman Primate Eyes for Histological Evaluation After Retinal Gene Transfer. Human Gene Therapy Methods, 2018, 29, 115-123.	2.1	0
61	Standardized Method for Intra-Cisterna Magna Delivery Under Fluoroscopic Guidance in Nonhuman Primates. Human Gene Therapy Methods, 2018, 29, 212-219.	2.1	17
62	Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques. Molecular Therapy - Methods and Clinical Development, 2018, 10, 79-88.	4.1	79
63	Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nature Biotechnology, 2018, 36, 717-725.	17.5	95
64	Preclinical development of a platform for enzyme therapy in the CNS of MPS I and MPS II patients based on intrathecal AAV delivery. Molecular Genetics and Metabolism, 2018, 123, S64.	1.1	0
65	Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques. Molecular Therapy - Methods and Clinical Development, 2018, 10, 68-78.	4.1	60
66	Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors. Journal of Virology, 2018, 92, .	3.4	33
67	Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome. Molecular Therapy - Methods and Clinical Development, 2018, 10, 237-244.	4.1	10
68	Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques. Human Gene Therapy, 2018, 29, 1364-1375.	2.7	18
69	Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice. Human Gene Therapy, 2017, 28, 392-402.	2.7	29
70	Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for Î±-1-antitrypsin deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1655-1659.	7.1	52
71	AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Molecular Genetics and Metabolism, 2017, 120, 299-305.	1.1	39
72	Jurassic Park, Gene Therapy, and Neuroscience: An Interview with Feng Zhang, PhD. Human Gene Therapy Clinical Development, 2017, 28, 4-6.	3.1	0

#	Article	IF	Citations
73	5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. Molecular Therapy, 2017, 25, 1387-1394.	8.2	84
74	Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes. Journal of Immunology, 2017, 198, 4581-4587.	0.8	1
75	The Past, Present, and Future of Gene Therapy from Nobel Laureate David Baltimore. Human Gene Therapy Clinical Development, 2017, 28, 65-67.	3.1	1
76	Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR^{+/â^'}Rhesus Macaques. Human Gene Therapy Clinical Development, 2017, 28, 39-50.	3.1	46
77	Regulatory and Exhausted T Cell Responses to AAV Capsid. Human Gene Therapy, 2017, 28, 338-349.	2.7	35
78	Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia. Human Gene Therapy Clinical Development, 2017, 28, 28-38.	3.1	33
79	Wnt10b and Dkk-1 gene therapy differentially influenced trabecular bone architecture, soft tissue integrity, and osteophytosis in a skeletally mature rat model of osteoarthritis. Connective Tissue Research, 2017, 58, 542-552.	2.3	11
80	Challenges in the gene therapy commercial ecosystem. Nature Biotechnology, 2017, 35, 813-815.	17.5	6
81	The Story of RNA Interference as a New Therapeutic Paradigm from Nobel Laureate Craig Mello. Human Gene Therapy Clinical Development, 2017, 28, 121-125.	3.1	0
82	Abnormal polyamine metabolism is unique to the neuropathic forms of MPS: potential for biomarker development and insight into pathogenesis. Human Molecular Genetics, 2017, 26, 3837-3849.	2.9	5
83	2017 Was the Year We Have Been Waiting For. Human Gene Therapy Clinical Development, 2017, 28, 165-166.	3.1	2
84	Carl June Speaks of His Pioneering Efforts That Led to the First Food and Drug Administrationâ€"Approved Gene Therapy Product. Human Gene Therapy Clinical Development, 2017, 28, 175-177.	3.1	1
85	The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute. Human Gene Therapy Clinical Development, 2017, 28, 178-186.	3.1	2
86	Effects of Self-Complementarity, Codon Optimization, Transgene, and Dose on Liver Transduction with AAV8. Human Gene Therapy Methods, 2016, 27, 228-237.	2.1	15
87	Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16079.	4.1	14
88	695. An AAV8 Mutant with Better Transduction in Murine Muscle and Nasal Airway Than AAV8. Molecular Therapy, 2016, 24, S275.	8.2	0
89	699. Effective AAV9 Vector Delivery to Nasal Mucosa for Protection Against Airborne Challenge with Influenza A and B. Molecular Therapy, 2016, 24, S276.	8.2	0
90	24. Sustained Expression with Partial Correction of Neutrophil Defects 5 Years After Intramuscular rAAV1 Gene Therapy for Alpha-1 Antitrypsin Deficiency. Molecular Therapy, 2016, 24, S11-S12.	8.2	3

#	Article	IF	Citations
91	60. Engineering AAV Vector for the Delivery of Human BuChE to Protect Against Exposure to Organophosphates. Molecular Therapy, 2016, 24, S26.	8.2	0
92	82. Mapping the Humoral Immune Response to AAV by Molecular Docking and Cryo-Electron Microscopy for the Design of Next-Generation AAV Vectors. Molecular Therapy, 2016, 24, S36.	8.2	0
93	189. Therapeutic Gene Transfer as a Treatment Option for Age-Related Macular Degeneration. Molecular Therapy, 2016, 24, S74.	8.2	0
94	227. A Dose-Escalating Preclinical Study to Determine the Efficacy, MED, and Safety of a Clinical Candidate Vector in a Mouse Model of Hemophilia B. Molecular Therapy, 2016, 24, S89.	8.2	0
95	346. AAV9 Delivery into Cerebrospinal Fluid Corrects CNS Disease in a Murine Model of Mucopolysaccharidosis Type II. Molecular Therapy, 2016, 24, S138-S139.	8.2	0
96	481. CRISPR/Cas9-Mediated In Vivo Genome Editing to Correct the OTC spfash Mutation in Newborn Mice. Molecular Therapy, 2016, 24, S190-S191.	8.2	0
97	696. TLR9 Signaling Mediates Transgene Antibody Formation. Molecular Therapy, 2016, 24, S275.	8.2	0
98	760. Optimized AAV-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice and Cynomolgus Macaques. Molecular Therapy, 2016, 24, S300.	8.2	0
99	Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, 1975-1979.	4.0	14
100	Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. Human Gene Therapy, 2016, 27, 906-915.	2.7	36
101	Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. Molecular Genetics and Metabolism, 2016, 119, 124-130.	1.1	34
102	Recollections from a Pioneer Who Provided the Foundation for the Success of Gene Therapy in Treating Severe Combined Immune Deficiencies. Human Gene Therapy Clinical Development, 2016, 27, 53-56.	3.1	1
103	Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine, 2016, 34, 6323-6329.	3.8	36
104	AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees. Human Gene Therapy Clinical Development, 2016, , .	3.1	1
105	AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Human Gene Therapy Clinical Development, 2016, 27, 79-82.	3.1	58
106	Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol. Cardiovascular Research, 2016, 110, 23-29.	3.8	12
107	Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Molecular Therapy, 2016, 24, 206-216.	8.2	70
108	Interview with Inder Verma, PhD. Human Gene Therapy Clinical Development, 2016, 27, 5-8.	3.1	1

#	Article	IF	Citations
109	Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia. Human Gene Therapy, 2016, 27, 345-353.	2.7	30
110	A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nature Biotechnology, 2016, 34, 334-338.	17.5	476
111	Crispr/Cas9-Mediated In Vivo Gene Targeting Corrects Haemostasis in Newborn and Adult FIX-KO Mice. Blood, 2016, 128, 1174-1174.	1.4	9
112	Strategies for Selection of AAV Vectors for Administration to Liver: Studies in Nonhuman Primates. Blood, 2016, 128, 2316-2316.	1.4	1
113	A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy and Mechanism Evaluation, 2016, 3, 1-210.	0.7	22
114	90. Identification of an Adeno-Associated Virus Binding Epitope for AVB Sepharose Affinity Resin. Molecular Therapy, 2015, 23, S38-S39.	8.2	2
115	174. Liver Fibrosis in Aged OTC-KO Heterozygotes and Successful Correction by AAV8-Mediated Gene Therapy. Molecular Therapy, 2015, 23, S69.	8.2	0
116	525. CD8+ T Cell Tolerance To Epitopes Downstream of Non-Sense Mutations. Molecular Therapy, 2015, 23, S210-S211.	8.2	0
117	646. Isolation and Evaluation of Novel Anti-AAV2 and AAV3B Antibody Clones from a Human Donor. Molecular Therapy, 2015, 23, S257.	8.2	0
118	Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15040.	4.1	31
119	There and Back Again: Mitchell Finer on the Journey of Biotech from Start-Up to Success. Human Gene Therapy Clinical Development, 2015, 26, 140-143.	3.1	2
120	A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow. Human Gene Therapy Clinical Development, 2015, 26, 203-207.	3.1	0
121	Perspectives on Best Practices for Gene Therapy Programs. Human Gene Therapy, 2015, 26, 127-133.	2.7	14
122	The Next Chapter. Human Gene Therapy, 2015, 26, 331-331.	2.7	1
123	A Call to Arms for Improved Vector Analytics!. Human Gene Therapy Methods, 2015, 26, 1-2.	2.1	6
124	Î²-Defensin 1 Plays a Role in Acute Mucosal Defense against Candida albicans. Journal of Immunology, 2015, 194, 1788-1795.	0.8	76
125	Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2015, 3, 684-691.	10.7	344
126	Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nature Communications, 2015, 6, 7339.	12.8	51

#	Article	IF	Citations
127	Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates. Molecular Therapy, 2015, 23, 1298-1307.	8.2	72
128	Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Human Gene Therapy Methods, 2015, 26, 103-105.	2.1	52
129	Motor Neuron Transduction After Intracisternal Delivery of AAV9 in a Cynomolgus Macaque. Human Gene Therapy Methods, 2015, 26, 43-44.	2.1	6
130	Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria. Journal of Immunological Methods, 2015, 427, 42-50.	1.4	30
131	Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Molecular Therapy, 2015, 23, 1877-1887.	8.2	94
132	Humoral and Cell-Mediated Immune Response, and Growth Factor Synthesis After Direct Intraarticular Injection of rAAV2-IGF-I and rAAV5-IGF-I in the Equine Middle Carpal Joint. Human Gene Therapy, 2015, 26, 161-171.	2.7	15
133	Structure of neurotropic adeno-associated virus AAVrh.8. Journal of Structural Biology, 2015, 192, 21-36.	2.8	47
134	Human Gene Therapy Clinical Development: Where the Academy and Industry Meet. Human Gene Therapy Clinical Development, 2015, 26, 139-139.	3.1	0
135	Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14051.	4.1	84
136	Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression. PLoS ONE, 2014, 9, e112268.	2.5	47
137	AAV Vectors Expressing LDLR Gain-of-Function Variants Demonstrate Increased Efficacy in Mouse Models of Familial Hypercholesterolemia. Circulation Research, 2014, 115, 591-599.	4.5	44
138	P204 Immune Responses To Single And Repeated Administration Of Pgm169/gl67a: The Uk Cf Gene Therapy Consortium Clinical Trials. Thorax, 2014, 69, A166-A166.	5.6	0
139	AAV8 Induces Tolerance in Murine Muscle as a Result of Poor APC Transduction, T Cell Exhaustion, and Minimal MHCI Upregulation on Target Cells. Molecular Therapy, 2014, 22, 28-41.	8.2	50
140	In VivoEvaluation of Adeno-Associated Virus Gene Transfer in Airways of Mice with Acute or Chronic Respiratory Infection. Human Gene Therapy, 2014, 25, 966-976.	2.7	10
141	Genetic Diseases, Immunology, Viruses, and Gene Therapy. Human Gene Therapy, 2014, 25, 257-261.	2.7	8
142	Formation of Newly Synthesized Adeno-Associated Virus Capsids in the Cell Nucleus. Human Gene Therapy Methods, 2014, 25, 179-180.	2.1	0
143	AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating. Virology, 2014, 454-455, 227-236.	2.4	14
144	Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 326-334.	2.0	41

#	Article	IF	Citations
145	Absolute Determination of Single-Stranded and Self-Complementary Adeno-Associated Viral Vector Genome Titers by Droplet Digital PCR. Human Gene Therapy Methods, 2014, 25, 115-125.	2.1	132
146	The First Journal on Human Gene Therapy Celebrates its 25th Anniversary. Human Gene Therapy, 2014, 25, 1-2.	2.7	5
147	Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14894-14899.	7.1	42
148	Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I. Molecular Therapy, 2014, 22, 2018-2027.	8.2	89
149	Adeno-Associated Virus 9-Mediated Airway Expression of Antibody Protects Old and Immunodeficient Mice against Influenza Virus. Vaccine Journal, 2014, 21, 1528-1533.	3.1	31
150	Increased Mucosal CD4 ⁺ T Cell Activation in Rhesus Macaques following Vaccination with an Adenoviral Vector. Journal of Virology, 2014, 88, 8468-8478.	3.4	29
151	The special case of gene therapy pricing. Nature Biotechnology, 2014, 32, 874-876.	17.5	66
152	The structure of AAVrh32.33, a novel gene delivery vector. Journal of Structural Biology, 2014, 186, 308-317.	2.8	31
153	An AAV Vector-Mediated Gene Delivery Approach Facilitates Reconstitution of Functional Human CD8+ T Cells in Mice. PLoS ONE, 2014, 9, e88205.	2.5	43
154	Lessons Learned from the Clinical Development and Market Authorization of Glybera. Human Gene Therapy Clinical Development, 2013, 24, 55-64.	3.1	154
155	Enhancing the Utility of Adeno-Associated Virus Gene Transfer through Inducible Tissue-Specific Expression. Human Gene Therapy Methods, 2013, 24, 270-278.	2.1	26
156	Self-Reactive CFTR T Cells in Humans: Implications for Gene Therapy. Human Gene Therapy Clinical Development, 2013, 24, 108-115.	3.1	8
157	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	7.1	247
158	Bulls, Bubbles, and Biotech. Human Gene Therapy, 2013, 24, 715-716.	2.7	6
159	Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8. Human Gene Therapy, 2013, 24, 163-169.	2.7	38
160	Single Nucleotide Polymorphisms in Cholesteryl Ester Transfer Protein Gene and Recurrent Coronary Heart Disease or Mortality in Patients With Established Atherosclerosis. American Journal of Cardiology, 2013, 112, 1287-1292.	1.6	6
161	Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. Molecular Therapy, 2013, 21, 266-268.	8.2	12
162	Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza. Science Translational Medicine, 2013, 5, 187ra72.	12.4	99

#	Article	IF	Citations
163	The Role of Apoptosis in Immune Hyporesponsiveness Following AAV8 Liver Gene Transfer. Molecular Therapy, 2013, 21, 2227-2235.	8.2	16
164	Multiple Recombinant Adeno-Associated Viral Vector Serotypes Display PersistentIn VivoGene Expression in Vector-Transduced Rat Stifle Joints. Human Gene Therapy Methods, 2013, 24, 185-194.	2.1	6
165	Flushing Out Antibodies to Make AAV Gene Therapy Available to More Patients. Molecular Therapy, 2013, 21, 269-271.	8.2	5
166	Advancing Translational Research Through the NHLBI Gene Therapy Resource Program (GTRP). Human Gene Therapy Clinical Development, 2013, 24, 5-10.	3.1	4
167	Humoral Immune Response to AAV. Frontiers in Immunology, 2013, 4, 341.	4.8	190
168	Vectored Expression of the Broadly Neutralizing Antibody FI6 in Mouse Airway Provides Partial Protection against a New Avian Influenza A Virus, H7N9. Vaccine Journal, 2013, 20, 1836-1837.	3.1	24
169	Mapping the Structural Determinants Responsible for Enhanced T Cell Activation to the Immunogenic Adeno-Associated Virus Capsid from Isolate Rhesus 32.33. Journal of Virology, 2013, 87, 9473-9485.	3.4	24
170	Recombinant Adeno-Associated Virus Integration Sites in Murine Liver After Ornithine Transcarbamylase Gene Correction. Human Gene Therapy, 2013, 24, 520-525.	2.7	40
171	Biodistribution of AAV8 Vectors Expressing Human Low-Density Lipoprotein Receptor in a Mouse Model of Homozygous Familial Hypercholesterolemia. Human Gene Therapy Clinical Development, 2013, 24, 154-160.	3.1	34
172	Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial Hypercholesterolemia. Human Gene Therapy, 2013, 24, 19-26.	2.7	65
173	Vector Sequences Are Not Detected in Tumor Tissue from Research Subjects with Ornithine Transcarbamylase Deficiency Who Previously Received Adenovirus Gene Transfer. Human Gene Therapy, 2013, 24, 814-819.	2.7	3
174	In Memory of Sonia Skarlatos, PhD (1953â€“2013). Human Gene Therapy, 2013, 24, 895-895.	2.7	0
175	Is This Gene Therapy's Breakout Moment?. Genetic Engineering and Biotechnology News, 2013, 33, 62-62.	0.1	1
176	AAV9 Targets Cone Photoreceptors in the Nonhuman Primate Retina. PLoS ONE, 2013, 8, e53463.	2.5	85
177	CpG-depleted adeno-associated virus vectors evade immune detection. Journal of Clinical Investigation, 2013, 123, 2994-3001.	8.2	182
178	Human Treg responses allow sustained recombinant adeno-associated virusâ€“mediated transgene expression. Journal of Clinical Investigation, 2013, 123, 5310-5318.	8.2	133
179	Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid. Journal of Virology, 2012, 86, 7326-7333.	3.4	101
180	Analysis of Particle Content of Recombinant Adeno-Associated Virus Serotype 8 Vectors by Ion-Exchange Chromatography. Human Gene Therapy Methods, 2012, 23, 56-64.	2.1	74

#	Article	IF	Citations
181	A New Open Access Partner. Human Gene Therapy, 2012, 23, 437-437.	2.7	0
182	Hepatic Gene Transfer in Neonatal Mice by Adeno-Associated Virus Serotype 8 Vector. Human Gene Therapy, 2012, 23, 533-539.	2.7	90
183	Sustained correction of OTC deficiency in spfash mice using optimized self-complementary AAV2/8 vectors. Gene Therapy, 2012, 19, 404-410.	4.5	38
184	Moving to the Clinic with Gene Therapy Through Our New Journal Expansion, Human Gene Therapy Clinical Development. Human Gene Therapy, 2012, 23, 1029-1030.	2.7	3
185	Influence of serotype, cell type, tissue composition, and time after inoculation on gene expression in recombinant adeno-associated viral vectorâ€“transduced equine joint tissues. American Journal of Veterinary Research, 2012, 73, 1178-1185.	0.6	18
186	Chromosome 9p21 Single Nucleotide Polymorphisms Are Not Associated With Recurrent Myocardial Infarction in Patients With Established Coronary Artery Disease. Circulation Journal, 2012, 76, 950-956.	1.6	24
187	Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Molecular Genetics and Metabolism, 2012, 105, 263-265.	1.1	34
188	Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Molecular Genetics and Metabolism, 2012, 105, 203-211.	1.1	46
189	Pseudotyped adenoâ€associated viral vector tropism and transduction efficiencies in murine wound healing. Wound Repair and Regeneration, 2012, 20, 592-600.	3.0	17
190	Long-term Restoration of Cardiac Dystrophin Expression in Golden Retriever Muscular Dystrophy Following rAAV6-mediated Exon Skipping. Molecular Therapy, 2012, 20, 580-589.	8.2	74
191	It's Time for Gene Therapy to Get Disruptive!. Human Gene Therapy, 2012, 23, 1-3.	2.7	13
192	Increased mucosal CD4+ T-cell activation following vaccination with an adenoviral vector in rhesus macaques. Retrovirology, 2012, 9, .	2.0	1
193	Adenoviruses in Fecal Samples from Asymptomatic Rhesus Macaques, United States. Emerging Infectious Diseases, 2012, 18, 1081-1088.	4.3	30
194	RPGR-Associated Retinal Degeneration in Human X-Linked RP and a Murine Model. , 2012, 53, 5594.		56
195	Pseudotyped AAV Vector-Mediated Gene Transfer in a Human Fetal Trachea Xenograft Model: Implications for In Utero Gene Therapy for Cystic Fibrosis. PLoS ONE, 2012, 7, e43633.	2.5	19
196	Inflammation Promotes the Loss of Adeno-Associated Virusâ€“Mediated Transgene Expression in Mouse Liver. Gastroenterology, 2011, 141, 348-357.e3.	1.3	31
197	Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Therapy, 2011, 18, 517-527.	4.5	78
198	Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Molecular Genetics and Metabolism, 2011, 104, 395-403.	1.1	58

#	Article	IF	Citations
199	Adenoviruses in Lymphocytes of the Human Gastro-Intestinal Tract. PLoS ONE, 2011, 6, e24859.	2.5	60
200	Muscleâ€directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. Journal of Thrombosis and Haemostasis, 2011, 9, 2009-2019.	3.8	20
201	Usefulness of Single Nucleotide Polymorphism in Chromosome 4q25 to Predict In-Hospital and Long-Term Development of Atrial Fibrillation and Survival in Patients Undergoing Coronary Artery Bypass Grafting. American Journal of Cardiology, 2011, 107, 1504-1509.	1.6	39
202	Creation of a panel of vectors based on ape adenovirus isolates. Journal of Gene Medicine, 2011, 13, 17-25.	2.8	33
203	AAV8-mediated Hepatic Gene Transfer in Infant Rhesus Monkeys (Macaca mulatta). Molecular Therapy, 2011, 19, 2012-2020.	8.2	85
204	A New Editorial Team. Human Gene Therapy, 2011, 22, 785-785.	2.7	0
205	Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing Î±₁-Antitrypsin: Interim Results. Human Gene Therapy, 2011, 22, 1239-1247.	2.7	297
206	Cardiac Gene Transfer of Short Hairpin RNA Directed Against Phospholamban Effectively Knocks Down Gene Expression but Causes Cellular Toxicity in Canines. Human Gene Therapy, 2011, 22, 969-977.	2.7	43
207	Impact of Pre-Existing Immunity on Gene Transfer to Nonhuman Primate Liver with Adeno-Associated Virus 8 Vectors. Human Gene Therapy, 2011, 22, 1389-1401.	2.7	170
208	The Birth of Human Gene Therapy Methods. Human Gene Therapy, 2011, 22, 1031-1032.	2.7	2
209	HumanCRB1-Associated Retinal Degeneration: Comparison with therd8 Crb1-Mutant Mouse Model. , 2011, 52, 6898.		98
210	Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey. Science Translational Medicine, 2011, 3, 88ra54.	12.4	179
211	Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents. Vaccine Journal, 2011, 18, 1586-1588.	3.1	269
212	Construction of gene transfer vectors based on simian adenovirus 7. Journal of General Virology, 2011, 92, 1749-1753.	2.9	11
213	Evaluation of Adeno-Associated Viral Vectors for Liver-Directed Gene Transfer in Dogs. Human Gene Therapy, 2011, 22, 985-997.	2.7	35
214	The Technology of Gene Therapy. Human Gene Therapy, 2011, 22, 117-117.	2.7	0
215	The History and Promise of Gene Therapy. Genetic Engineering and Biotechnology News, 2011, 31, 62-65.	0.1	2
216	Identification and functional characterization in vivo of a novel splice variant of LDLR in rhesus macaques. Physiological Genomics, 2011, 43, 911-916.	2.3	3

#	Article	IF	Citations
217	The Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products. Molecular Therapy, 2011, 19, 16-27.	8.2	113
218	The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. Journal of Clinical Investigation, 2011, 121, 2427-2435.	8.2	150
219	In the Beginning: Reflections on the Genesis of Molecular Therapy. Molecular Therapy, 2010, 18, 9-10.	8.2	1
220	Gene Therapy in a Humanized Mouse Model of Familial Hypercholesterolemia Leads to Marked Regression of Atherosclerosis. PLoS ONE, 2010, 5, e13424.	2.5	69
221	New Candidate Vaccines against Blood-StagePlasmodium falciparumMalaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1. Infection and Immunity, 2010, 78, 4601-4612.	2.2	46
222	Molecular Analysis of Vector Genome Structures After Liver Transduction by Conventional and Self-Complementary Adeno-Associated Viral Serotype Vectors in Murine and Nonhuman Primate Models. Human Gene Therapy, 2010, 21, 750-761.	2.7	36
223	Activation of Transgene-specific T Cells Following Lentivirus-mediated Gene Delivery to Mouse Lung. Molecular Therapy, 2010, 18, 143-150.	8.2	35
224	Î±-Fetoprotein Gene Delivery to the Nasal Epithelium of Nonhuman Primates by Human Parainfluenza Viral Vectors. Human Gene Therapy, 2010, 21, 1657-1664.	2.7	8
225	Efficient Serotype-Dependent Release of Functional Vector into the Culture Medium During Adeno-Associated Virus Manufacturing. Human Gene Therapy, 2010, 21, 1251-1257.	2.7	117
226	AAV Vectors Avoid Inflammatory Signals Necessary to Render Transduced Hepatocyte Targets for Destructive T Cells. Molecular Therapy, 2010, 18, 977-982.	8.2	49
227	Systematic Evaluation of AAV Vectors for Liver directed Gene Transfer in Murine Models. Molecular Therapy, 2010, 18, 118-125.	8.2	110
228	Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clinical Lipidology, 2010, 5, 793-809.	0.4	13
229	The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques. Molecular Therapy, 2010, 18, 126-134.	8.2	123
230	Efficient Gene Transfer Into the Mouse Lung by Fetal Intratracheal Injection of rAAV2/6.2. Molecular Therapy, 2010, 18, 2130-2138.	8.2	33
231	Autoimmunity, Recessive Diseases, and Gene Replacement Therapy. Molecular Therapy, 2010, 18, 2045-2047.	8.2	6
232	Dual Reporter Comparative Indexing of rAAV Pseudotyped Vectors in Chimpanzee Airway. Molecular Therapy, 2010, 18, 594-600.	8.2	49
233	BALB/c Mice Show Impaired Hepatic Tolerogenic Response Following AAV Gene Transfer to the Liver. Molecular Therapy, 2010, 18, 766-774.	8.2	29
234	Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale. Human Gene Therapy, 2010, 21, 1259-1271.	2.7	283

#	Article	IF	Citations
235	Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine, 2010, 28, 5669-5675.	3.8	20
236	Preoperative Statin Therapy Decreases Risk of Postoperative Renal Insufficiency. Cardiovascular Therapeutics, 2010, 28, 80-86.	2.5	41
237	Host Immune Responses to Chronic Adenovirus Infections in Human and Nonhuman Primates. Journal of Virology, 2009, 83, 2623-2631.	3.4	61
238	Worldwide Epidemiology of Neutralizing Antibodies to Adenoâ€Associated Viruses. Journal of Infectious Diseases, 2009, 199, 381-390.	4.0	632
239	Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins. Journal of Immunology, 2009, 182, 6051-6060.	0.8	79
240	Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16363-16368.	7.1	295
241	Functional Cystic Fibrosis Transmembrane Conductance Regulator Expression in Cystic Fibrosis Airway Epithelial Cells by AAV6.2-Mediated SegmentalTrans-Splicing. Human Gene Therapy, 2009, 20, 267-281.	2.7	55
242	A New Genetic Vaccine Platform Based on an Adeno-Associated Virus Isolated from a Rhesus Macaque. Journal of Virology, 2009, 83, 12738-12750.	3.4	55
243	Adeno-Associated Virus-Mediated Gene Transfer to Nonhuman Primate Liver Can Elicit Destructive Transgene-Specific T Cell Responses. Human Gene Therapy, 2009, 20, 930-942.	2.7	88
244	Transduction Efficiencies of Novel AAV Vectors in Mouse Airway Epithelium In Vivo and Human Ciliated Airway Epithelium In Vitro. Molecular Therapy, 2009, 17, 294-301.	8.2	153
245	Cationic Lipid Formulations Alter the In Vivo Tropism of AAV2/9 Vector in Lung. Molecular Therapy, 2009, 17, 2078-2087.	8.2	23
246	Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates. PLoS Pathogens, 2009, 5, e1000503.	4.7	126
247	Effect of Preexisting Immunity on an Adenovirus Vaccine Vector: In Vitro Neutralization Assays Fail To Predict Inhibition by Antiviral Antibody In Vivo. Journal of Virology, 2009, 83, 5567-5573.	3.4	55
248	Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology, 2009, 50, 612-621.	7.3	226
249	Identification of the murine AAVrh32.33 capsidâ€specific CD8+ T cell epitopes. Journal of Gene Medicine, 2009, 11, 1095-1102.	2.8	10
250	Tailoring the AAV vector capsid for gene therapy. Gene Therapy, 2009, 16, 311-319.	4.5	152
251	Identification of the murine firefly luciferase-specific CD8 T-cell epitopes. Gene Therapy, 2009, 16, 441-447.	4.5	57
252	Identification of the immunodominant cytotoxic T-cell epitope of human -1 antitrypsin. Gene Therapy, 2009, 16, 1380-1382.	4.5	3

#	Article	IF	Citations
253	Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Therapy, 2009, 16, 1416-1428.	4.5	59
254	A History Lesson for Stem Cells. Science, 2009, 324, 727-728.	12.6	94
255	Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Molecular Genetics and Metabolism, 2009, 96, 151-157.	1.1	246
256	Adenovirusâ€“Adeno-Associated Virus Hybrid for Large-Scale Recombinant Adeno-Associated Virus Production. Human Gene Therapy, 2009, 20, 922-929.	2.7	43
257	When Selecting an Adenoâ€associated Viral Vector Serotype, Cell Monolayer Transduction Efficiency Does Not Accurately Predict Tissue Transduction Efficiency in Equine Synovial Tissues. FASEB Journal, 2009, 23, 817.7.	0.5	1
258	Novel AAV serotypes for improved ocular gene transfer. Journal of Gene Medicine, 2008, 10, 375-382.	2.8	180
259	Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia. American Journal of Cardiology, 2008, 102, 1438-1443.	1.6	146
260	Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. Brain Research, 2008, 1190, 15-22.	2.2	69
261	Adenovirus-Based Vaccines Generate Cytotoxic T Lymphocytes to Epitopes of NS1 from Dengue Virus That Are Present in All Major Serotypes. Human Gene Therapy, 2008, 19, 927-936.	2.7	32
262	HCO3â˜’ Secretion by Murine Nasal Submucosal Gland Serous Acinar Cells during Ca2+-stimulated Fluid Secretion. Journal of General Physiology, 2008, 132, 161-183.	1.9	23
263	Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat. Human Gene Therapy, 2008, 19, 1359-1368.	2.7	247
264	Single-Dose Protection againstPlasmodium bergheiby a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A. Journal of Virology, 2008, 82, 3822-3833.	3.4	67
265	Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15112-15117.	7.1	639
266	Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain. Molecular Therapy, 2008, 16, 1710-1718.	8.2	152
267	Percutaneous Transendocardial Delivery of Self-complementary Adeno-associated Virus 6 Achieves Global Cardiac Gene Transfer in Canines. Molecular Therapy, 2008, 16, 1953-1959.	8.2	72
268	Impact of Preexisting Vector Immunity on the Efficacy of Adeno-Associated Virus-Based HIV-1 Gag Vaccines. Human Gene Therapy, 2008, 19, 663-669.	2.7	49
269	ADENOVIRUS BASED VACCINES GENERATE CYTOTOXIC T LYMPHOCYTES TO EPITOPES OF NS1 FROM DENGUE VIRUS THAT ARE PRESENT IN ALL MAJOR SEROTYPES. Human Gene Therapy, 2008, .	2.7	0
270	Mucosal Delivery of Adenovirusâ€Based Vaccine Protects against Ebola Virus Infection in Mice. Journal of Infectious Diseases, 2007, 196, S413-S420.	4.0	53

#	Article	IF	Citations
271	Human Immunodeficiency Viral Vector Pseudotyped with the Spike Envelope of Severe Acute Respiratory Syndrome Coronavirus Transduces Human Airway Epithelial Cells and Dendritic Cells. Human Gene Therapy, 2007, 18, 413-422.	2.7	26
272	Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8⁺T-Cell Responses in Mice. Journal of Virology, 2007, 81, 11840-11849.	3.4	57
273	Human cone photoreceptor dependence on RPE65 isomerase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15123-15128.	7.1	135
274	The p38 Mitogen-Activated Protein Kinase Signaling Pathway Is Coupled to Toll-Like Receptor 5 To Mediate Gene Regulation in Response toPseudomonas aeruginosaInfection in Human Airway Epithelial Cells. Infection and Immunity, 2007, 75, 5985-5992.	2.2	37
275	AAV as An Immunogen. Current Gene Therapy, 2007, 7, 325-333.	2.0	67
276	A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine Carrier. Molecular Therapy, 2007, 15, 608-617.	8.2	34
277	Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector. Molecular Therapy, 2007, 15, 481-491.	8.2	153
278	Activation of CFTR-specific T Cells in Cystic Fibrosis Mice Following Gene Transfer. Molecular Therapy, 2007, 15, 1694-1700.	8.2	22
279	Prediction of Cellular Immune Responses against CFTR in Patients with Cystic Fibrosis after Gene Therapy. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 529-533.	2.9	18
280	Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic Targets. Human Gene Therapy, 2007, 18, 185-194.	2.7	105
281	Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors. Journal of Virology, 2007, 81, 11372-11380.	3.4	210
282	Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine, 2007, 25, 5220-5231.	3.8	68
283	Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine, 2007, 25, 6845-6851.	3.8	77
284	Structure-Based Identification of a Major Neutralizing Site in an Adenovirus Hexon. Journal of Virology, 2007, 81, 1680-1689.	3.4	90
285	Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain. Human Gene Therapy, 2007, 18, 195-206.	2.7	273
286	Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovascular Diabetology, 2007, 6, 15.	6.8	64
287	Optical imaging of Ca2+-evoked fluid secretion by murine nasal submucosal gland serous acinar cells. Journal of Physiology, 2007, 582, 1099-1124.	2.9	28
288	Gene transfer in human skin with different pseudotyped HIV-based vectors. Gene Therapy, 2007, 14, 648-656.	4.5	27

#	Article	IF	Citations
289	Pulmonary delivery of adenovirus vector formulated with dexamethasoneâ€“spermine facilitates homologous vector re-administration. Gene Therapy, 2007, 14, 1594-1604.	4.5	23
290	Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. Journal of Thrombosis and Haemostasis, 2007, 5, 16-24.	3.8	170
291	Rescue of chimeric adenoviral vectors to expand the serotype repertoire. Journal of Virological Methods, 2007, 141, 14-21.	2.1	6
292	A Comparative Analysis of Novel Fluorescent Proteins as Reporters for Gene Transfer Studies. Journal of Histochemistry and Cytochemistry, 2007, 55, 931-939.	2.5	24
293	Detection of Reporter Gene Expression in Murine Airways. , 2007, 411, 25-34.		3
294	Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nature Medicine, 2006, 12, 967-971.	30.7	193
295	Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Therapy, 2006, 13, 421-429.	4.5	91
296	Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology, 2006, 346, 394-401.	2.4	121
297	High-Level Transgene Expression in Nonhuman Primate Liver with Novel Adeno-Associated Virus Serotypes Containing Self-Complementary Genomes. Journal of Virology, 2006, 80, 6192-6194.	3.4	73
298	Identification of Novel Adeno-Associated Virus Serotypes for Use as Vectors. , 2006, , 17-24.		0
299	A Common Mechanism for Cytoplasmic Dynein-Dependent Microtubule Binding Shared among Adeno-Associated Virus and Adenovirus Serotypes. Journal of Virology, 2006, 80, 7781-7785.	3.4	53
300	Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1852-1857.	2.4	52
301	Efficacy of Severe Acute Respiratory Syndrome Vaccine Based on a Nonhuman Primate Adenovirus in the Presence of Immunity Against Human Adenovirus. Human Gene Therapy, 2006, 17, 500-506.	2.7	47
302	Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates. Molecular Therapy, 2006, 13, 77-87.	8.2	161
303	High Levels of Persistent Expression of Î±1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh.10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated Viruses. Molecular Therapy, 2006, 13, 67-76.	8.2	121
304	Analysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to Liver. Molecular Therapy, 2006, 14, 34-44.	8.2	137
305	Long-Term Correction of Ammonia Metabolism and Prolonged Survival in Ornithine Transcarbamylase-Deficient Mice Following Liver-Directed Treatment with Adeno-associated Viral Vectors. Molecular Therapy, 2006, 14, 25-33.	8.2	76
306	Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12993-12998.	7.1	141

#	Article	IF	Citations
307	Generation of an adenoviral vaccine vector based on simian adenovirus 21. Journal of General Virology, 2006, 87, 2477-2485.	2.9	46
308	Efficacy of Severe Acute Respiratory Syndrome Vaccine Based on a Nonhuman Primate Adenovirus in the Presence of Immunity Against Human Adenovirus. Human Gene Therapy, 2006, .	2.7	0
309	Innate Immune Responses to Adenoviral Vector-Mediated Acute Pancreatitis. Pancreas, 2005, 30, 122-129.	1.1	22
310	Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood, 2005, 105, 1424-1430.	1.4	258
311	Utility of PEGylated recombinant adeno-associated viruses for gene transfer. Journal of Controlled Release, 2005, 108, 161-177.	9.9	68
312	Use of chimeric adenoviral vectors to assess capsid neutralization determinants. Virology, 2005, 333, 207-214.	2.4	35
313	Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology, 2005, 335, 34-45.	2.4	78
314	Transduction of satellite cells after prenatal intramuscular administration of lentiviral vectors. Journal of Gene Medicine, 2005, 7, 50-58.	2.8	44
315	Gene transfer into skeletal muscle using novel AAV serotypes. Journal of Gene Medicine, 2005, 7, 442-451.	2.8	108
316	An optimized protocol for detection of E. coli Î²-galactosidase in lung tissue following gene transfer. Histochemistry and Cell Biology, 2005, 124, 77-85.	1.7	38
317	Human Airway Epithelial Cells SensePseudomonas aeruginosaInfection via Recognition of Flagellin by Toll-Like Receptor 5. Infection and Immunity, 2005, 73, 7151-7160.	2.2	179
318	New Recombinant Serotypes of AAV Vectors. Current Gene Therapy, 2005, 5, 285-297.	2.0	461
319	Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naÃ¯ve and pre-immunized mice. Gene Therapy, 2005, 12, 427-436.	4.5	107
320	Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 560-565.	2.4	74
321	Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood, 2005, 105, 3079-3086.	1.4	162
322	Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity. Infection and Immunity, 2005, 73, 6885-6891.	2.2	54
323	Creatine Kinase, a Magnetic Resonance-Detectable Marker Gene for Quantification of Liver-Directed Gene Transfer. Human Gene Therapy, 2005, 16, 1429-1438.	2.7	25
324	Widespread Dispersion of Adeno-Associated Virus Serotype 1 and Adeno-Associated Virus Serotype 6 Vectors in the Rat Central Nervous System and in Human Glioblastoma Multiforme Xenografts. Human Gene Therapy, 2005, 16, 381-392.	2.7	26

#	Article	IF	Citations
325	No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in Mice. Molecular Therapy, 2005, 12, 299-306.	8.2	103
326	Proteasome Inhibition Enhances AAV-Mediated Transgene Expression in Human Synoviocytes in Vitro and in Vivo. Molecular Therapy, 2005, 11, 600-607.	8.2	55
327	Targeting Viral-Mediated Transduction to the Lung Airway Epithelium with the Anti-inflammatory Cationic Lipid Dexamethasoneâ€“Spermine. Molecular Therapy, 2005, 12, 502-509.	8.2	22
328	Pharmacologically Regulated Regeneration of Functional Human Pancreatic Islets. Molecular Therapy, 2005, 11, 105-111.	8.2	14
329	Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy. Clinical Cancer Research, 2005, 11, 7444-7453.	7.0	125
330	Nonhuman Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Overexpression of Vascular Endothelial Growth Factor. Diabetes, 2005, 54, 1141-1149.	0.6	64
331	Long-Term Inducible Gene Expression in the Eye via Adeno-Associated Virus Gene Transfer in Nonhuman Primates. Human Gene Therapy, 2005, 16, 178-186.	2.7	115
332	Adenovirus-Based Genetic Vaccines for Biodefense. Human Gene Therapy, 2005, 16, 157-168.	2.7	52
333	Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRÎ±. Cell Metabolism, 2005, 1, 297-308.	16.2	46
334	Creatine Kinase, a Magnetic Resonance-Detectable Marker Gene for Quantification of Liver-Directed Gene Transfer. Human Gene Therapy, 2005, .	2.7	0
335	SARS vaccine: progress and challenge. Cellular and Molecular Immunology, 2005, 2, 101-5.	10.5	10
336	498. Targeted Gene Transfer to Lung Airway Epithelium Using Plasmid or Adenoviral Vectors Formulated with an Anti-Inflammatory Dexamethasone-Spermine Conjugate. Molecular Therapy, 2004, 9, S189.	8.2	0
337	558. Anti-SARS Humoral and Cellular Immunity Evoked by an Adenovirus Vector Expressing Spike Glycoprotein from SARS Coronavirus. Molecular Therapy, 2004, 9, S210.	8.2	2
338	1015. Induction of Protective Immunity to Anthrax Lethal Toxin with a Chimpanzee Adenovirus-Based Vaccine Carrier in the Presence of Pre-Existing Anti-Human Adenovirus Immunity. Molecular Therapy, 2004, 9, S389.	8.2	0
339	161. Novel Pseudotyped AAV Vectors for Hemophilia B Gene Therapy. Molecular Therapy, 2004, 9, S61-S62.	8.2	0
340	368. Pseudotyping HIV Vector with the Spike Envelope Protein of SARS-CoV for Studying Viral Tropism, Immunology and Gene Therapy Applications. Molecular Therapy, 2004, 9, S140.	8.2	0
341	692. A Novel AAV Vector for the Treatment of Cystic Fibrosis Airway Disease. Molecular Therapy, 2004, 9, S262-S263.	8.2	0
342	90. Evaluation of Novel Gene Transfer Vectors Derived from Infectious Molecular Clones of Primate AAVs. Molecular Therapy, 2004, 9, S36.	8.2	0

#	Article	IF	Citations
343	568. Comparison of Antigen-Specific Immune Responses Elicited by Recombinant Simian Adenoviral Vectors with Deletions in Either E1, or E1/E3, or E1/E4 Regions. Molecular Therapy, 2004, 9, S214.	8.2	0
344	1016. Novel Chimeric Adenovirus Vaccine Vectors. Molecular Therapy, 2004, 9, S389.	8.2	1
345	Characterization of a Family of Chimpanzee Adenoviruses and Development of Molecular Clones for Gene Transfer Vectors. Human Gene Therapy, 2004, 15, 519-530.	2.7	86
346	373. Simian Adenoviral Vector Based-Vaccine Fully Protect Against Ebola Virus Even in the Presence of Pre-Existing Immunity to Human Adenovirus. Molecular Therapy, 2004, 9, S142.	8.2	0
347	PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum. Journal of Virology, 2004, 78, 912-921.	3.4	143
348	Macaque Model for Severe Acute Respiratory Syndrome. Journal of Virology, 2004, 78, 11401-11404.	3.4	125
349	Resolution of Primary Severe Acute Respiratory Syndrome-Associated Coronavirus Infection Requires Stat1. Journal of Virology, 2004, 78, 11416-11421.	3.4	132
350	Combined 5-Fluorouracil/Systemic Interferon-Î² Gene Therapy Results in Long-Term Survival in Mice with Established Colorectal Liver Metastases. Clinical Cancer Research, 2004, 10, 1535-1544.	7.0	27
351	Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes. Journal of Virology, 2004, 78, 7392-7399.	3.4	87
352	Generation of a Mouse Expressing a Conditional Knockout of the Hepatocyte Growth Factor Gene: Demonstration of Impaired Liver Regeneration. DNA and Cell Biology, 2004, 23, 592-603.	1.9	35
353	Adeno-associated Virus and Lentivirus Pseudotypes for Lung-directed Gene Therapy. Proceedings of the American Thoracic Society, 2004, 1, 309-314.	3.5	19
354	Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues. Journal of Virology, 2004, 78, 6381-6388.	3.4	900
355	AAV2 Vector Harboring a Liver-Restricted Promoter Facilitates Sustained Expression of Therapeutic Levels of Î±-Galactosidase A and the Induction of Immune Tolerance in Fabry Mice. Molecular Therapy, 2004, 9, 231-240.	8.2	127
356	Complete nucleotide sequences and genome organization of four chimpanzee adenoviruses. Virology, 2004, 324, 361-372.	2.4	45
357	Perceived quality of life in schizophrenia: Relationships to sleep quality. Quality of Life Research, 2004, 13, 783-791.	3.1	127
358	Novel adenoviral vectors coding for GFP-tagged wtCFTR and ?F508-CFTR: characterization of expression and electrophysiological properties in A549 cells. Pflugers Archiv European Journal of Physiology, 2004, 449, 278-87.	2.8	11
359	Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. Journal of Gene Medicine, 2004, 6, 663-672.	2.8	91
360	Mr and fluorescent imaging of low-density lipoprotein receptors1. Academic Radiology, 2004, 11, 1251-1259.	2.5	74

#	Article	IF	Citations
361	Transduction of Human Islets with Pseudotyped Lentiviral Vectors. Human Gene Therapy, 2004, 15, 211-219.	2.7	44
362	Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine, 2004, 22, 697-703.	3.8	34
363	Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. Modern Rheumatology, 2004, 14, 18-24.	1.8	9
364	Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood, 2004, 103, 1253-1260.	1.4	188
365	Autoimmune anemia in macaques following erythropoietin gene therapy. Blood, 2004, 103, 3303-3304.	1.4	115
366	Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood, 2004, 103, 3300-3302.	1.4	141
367	217. Widespread Distribution of Beta-Glucuronidase in the Mouse Brain Is Achieved after a Single Inoculation with a Neuroattenuated HSV Vector: Distribution Differs with Inoculation Site. Molecular Therapy, 2004, 9, S84.	8.2	1
368	1048. Long-Term Regulated Gene Expression in Non-Human Primates Using a Single Non-Recombinogenic AAV Vector. Molecular Therapy, 2004, 9, S402.	8.2	2
369	T Helper Cell-Independent Antibody Responses to the Transgene Product of an E1-Deleted Adenoviral Vaccine Require NK1.1 T Cells. Virology, 2003, 305, 397-405.	2.4	3
370	Cathelicidins - a family of multifunctional antimicrobial peptides. Cellular and Molecular Life Sciences, 2003, 60, 711-720.	5.4	364
371	Stroma Formation and Angiogenesis by Overexpression of Growth Factors, Cytokines, and Proteolytic Enzymes in Human Skin Grafted to SCID Mice. Journal of Investigative Dermatology, 2003, 120, 683-692.	0.7	44
372	High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells. Gene Therapy, 2003, 10, 1926-1930.	4.5	33
373	Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism, 2003, 80, 148-158.	1.1	1,309
374	Human fetal trachea-scid mouse xenografts: efficacy of vesicular stomatitis virus-G pseudotyped lentiviral-mediated gene transfer. Journal of Pediatric Surgery, 2003, 38, 834-839.	1.6	29
375	Correction of the Dystrophic Phenotype byIn VivoTargeting of Muscle Progenitor Cells. Human Gene Therapy, 2003, 14, 1441-1449.	2.7	53
376	Efficient Trans-Splicing in the Retina Expands the Utility of Adeno-Associated Virus as a Vector for Gene Therapy. Human Gene Therapy, 2003, 14, 37-44.	2.7	81
377	Efficient Transduction of Human Monocyte-Derived Dendritic Cells by Chimpanzee-Derived Adenoviral Vector. Human Gene Therapy, 2003, 14, 533-544.	2.7	26
378	Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier. Journal of Virology, 2003, 77, 10780-10789.	3.4	129

#	Article	IF	Citations
379	Delivery of Adeno-Associated Virus Vectors to the Fetal Retina: Impact of Viral Capsid Proteins on Retinal Neuronal Progenitor Transduction. Journal of Virology, 2003, 77, 7957-7963.	3.4	43
380	Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6081-6086.	7.1	293
381	Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Molecular Therapy, 2003, 8, 777-789.	8.2	105
382	Regulated expression of erythropoietin from an AAV vector safely improves the anemia of Î²-thalassemia in a mouse model. Molecular Therapy, 2003, 7, 493-497.	8.2	50
383	In Vivo Quantitative Noninvasive Imaging of Gene Transfer by Single-Photon Emission Computerized Tomography. Human Gene Therapy, 2003, 14, 255-261.	2.7	32
384	Airway epithelia regulate expression of human Î²â€defensin 2 through tollâ€like receptor 2. FASEB Journal, 2003, 17, 1727-1729.	0.5	96
385	Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers. Journal of Immunology, 2003, 171, 6774-6779.	0.8	107
386	Mucosally Delivered E1-Deleted Adenoviral Vaccine Carriers Induce Transgene Product-Specific Antibody Responses in Neonatal Mice. Journal of Immunology, 2003, 171, 4287-4293.	0.8	34
387	THE JIM INTERVIEW. Journal of Investigative Medicine, 2003, 51, 173-176.	1.6	0
388	A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag. Journal of Immunology, 2003, 170, 1416-1422.	0.8	193
389	Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Molecular Therapy, 2003, 8, 777.	8.2	7
390	Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. American Journal of Physiology - Cell Physiology, 2003, 284, C1297-C1308.	4.6	106
391	Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. Journal of General Virology, 2003, 84, 203-213.	2.9	27
392	IN VIVO SOMATIC CELL GENE TRANSFER OF AN ENGINEERED NOGGIN MUTEIN PREVENTS BMP4-INDUCED HETEROTOPIC OSSIFICATION. Journal of Bone and Joint Surgery - Series A, 2003, 85, 2332-2342.	3.0	128
393	Î²-Defensin 1 Contributes to Pulmonary Innate Immunity in Mice. Infection and Immunity, 2002, 70, 3068-3072.	2.2	220
394	A Pilot Study ofIn VivoLiver-Directed Gene Transfer with an Adenoviral Vector in Partial Ornithine Transcarbamylase Deficiency. Human Gene Therapy, 2002, 13, 163-175.	2.7	337
395	Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap. Molecular Therapy, 2002, 5, 644-649.	8.2	72
396	Toll-Like Receptor 4 Mediates Innate Immune Responses toHaemophilus influenzaeInfection in Mouse Lung. Journal of Immunology, 2002, 168, 810-815.	0.8	182

#	Article	IF	Citations
397	Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced Toxicity. Journal of Virology, 2002, 76, 5711-5719.	3.4	80
398	Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11854-11859.	7.1	1,398
399	Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product. Journal of Virology, 2002, 76, 2667-2675.	3.4	186
400	Natural Killer T Cell Ligand Î±-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines. Journal of Experimental Medicine, 2002, 195, 617-624.	8.5	321
401	Inhibition of Retinal Neovascularization by Intraocular Viral-Mediated Delivery of Anti-angiogenic Agents. Molecular Therapy, 2002, 6, 490-494.	8.2	144
402	Effect of Blood Collection Technique in Mice on Clinical Pathology Parameters. Human Gene Therapy, 2002, 13, 155-161.	2.7	121
403	PEGylation of E1-Deleted Adenovirus Vectors Allows Significant Gene Expression on Readministration to Liver. Human Gene Therapy, 2002, 13, 1887-1900.	2.7	166
404	Efficient Transduction of Liver and Muscle after in Utero Injection of Lentiviral Vectors with Different Pseudotypes. Molecular Therapy, 2002, 6, 349-358.	8.2	98
405	Targeted Transduction Patterns in the Mouse Brain by Lentivirus Vectors Pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV Envelope Proteins. Molecular Therapy, 2002, 5, 528-537.	8.2	198
406	Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye. Molecular Therapy, 2002, 6, 238-242.	8.2	94
407	Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Therapy, 2002, 9, 963-971.	4.5	81
408	Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nature Medicine, 2002, 8, 864-871.	30.7	344
409	A New Scalable Method for the Purification of Recombinant Adenovirus Vectors. Human Gene Therapy, 2002, 13, 1921-1934.	2.7	60
410	Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. Journal of General Virology, 2002, 83, 151-155.	2.9	57
411	Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. Journal of Clinical Investigation, 2002, 110, 499-504.	8.2	104
412	Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. Journal of Clinical Investigation, 2002, 110, 499-504.	8.2	24
413	Adenoviruses as Vectors for Human Gene Therapy. , 2002, , 31-49.		0
414	Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. Journal of Clinical Investigation, 2002, 110, 499-504.	8.2	76

#	Article	IF	Citations
415	Activation of Innate Immunity in Nonhuman Primates Following Intraportal Administration of Adenoviral Vectors. Molecular Therapy, 2001, 3, 708-722.	8.2	329
416	Isolation of Highly Infectious and Pure Adeno-Associated Virus Type 2 Vectors with a Single-Step Gravity-Flow Column. Human Gene Therapy, 2001, 12, 71-76.	2.7	278
417	iNOS Expression In Dystrophinopathies Can Be Reduced By Somatic Gene Transfer of Dystrophin or Utrophin. Molecular Medicine, 2001, 7, 355-364.	4.4	23
418	Construction of Adenoviral Vectors. Molecular Biotechnology, 2001, 18, 63-70.	2.4	27
419	Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nature Biotechnology, 2001, 19, 225-230.	17.5	300
420	Pharmacologically regulated gene expression in the retina following transduction with viral vectors. Gene Therapy, 2001, 8, 442-446.	4.5	31
421	Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Therapy, 2001, 8, 1281-1290.	4.5	156
422	Regulated Gene Expression in Gene Therapy. Annals of the New York Academy of Sciences, 2001, 953a, 53-63.	3.8	18
423	Adenovirus-mediated gene transfer to liver11The article was originally published in Advanced Drug Delivery Reviews 17 (1995) 303â€“307.. Advanced Drug Delivery Reviews, 2001, 46, 205-209.	13.7	39
424	â€œStealthâ€•Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung. Journal of Virology, 2001, 75, 4792-4801.	3.4	221
425	Biology of E1-Deleted Adenovirus Vectors in Nonhuman Primate Muscle. Journal of Virology, 2001, 75, 5222-5229.	3.4	32
426	Differences in the Human and Mouse Amino-Terminal Leader Peptides of Ornithine Transcarbamylase Affect Mitochondrial Import and Efficacy of Adenoviral Vectors. Human Gene Therapy, 2001, 12, 1035-1046.	2.7	10
427	Selective Repopulation of Normal Mouse Liver by Hepatocytes Transducedin Vivowith Recombinant Adeno-Associated Virus. Human Gene Therapy, 2001, 12, 45-50.	2.7	22
428	Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver. Molecular Therapy, 2001, 3, 28-35.	8.2	306
429	A Single-Step Affinity Column for Purification of Serotype-5 Based Adeno-associated Viral Vectors. Molecular Therapy, 2001, 4, 372-374.	8.2	84
430	In vivo detection of gene expression in liver by 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5205-5210.	7.1	55
431	Replication-Defective Vector Based on a Chimpanzee Adenovirus. Journal of Virology, 2001, 75, 11603-11613.	3.4	253
432	Development of Novel Formulations That Enhance Adenoviral-Mediated Gene Expression in the Lung in Vitro and in Vivo. Molecular Therapy, 2001, 4, 22-28.	8.2	46

#	Article	IF	Citations
433	Rhesus Monkey (Macaca mulatta) Mucosal Antimicrobial Peptides Are Close Homologues of Human Molecules. Vaccine Journal, 2001, 8, 370-375.	2.6	44
434	Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer. Journal of Virology, 2001, 75, 6199-6203.	3.4	203
435	Salt-Independent Abnormality of Antimicrobial Activity in Cystic Fibrosis Airway Surface Fluid. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 21-25.	2.9	75
436	Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Human Molecular Genetics, 2001, 10, 3075-3081.	2.9	335
437	Acute Cytokine Response to Systemic Adenoviral Vectors in Mice Is Mediated by Dendritic Cells and Macrophages. Molecular Therapy, 2001, 3, 697-707.	8.2	367
438	Intra-arterial Delivery of a Recombinant Adenovirus Does Not Increase Gene Transfer to Tumor Cells in a Rat Model of Metastatic Colorectal Carcinoma. Molecular Therapy, 2001, 4, 29-35.	8.2	16
439	Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies. Human Gene Therapy, 2001, 12, 205-215.	2.7	138
440	Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Journal of Clinical Investigation, 2001, 108, 83-95.	8.2	28
441	Systemic IFN-Î² gene therapy results in long-term survival in mice with established colorectal liver metastases. Journal of Clinical Investigation, 2001, 108, 83-95.	8.2	38
442	Production of recombinant adeno-associated virus. Advances in Virus Research, 2000, 55, 529-543.	2.1	17
443	Genotype spectrum of ornithine transcarbamylase deficiency: Correlation with the clinical and biochemical phenotype. American Journal of Medical Genetics Part A, 2000, 93, 313-319.	2.4	111
444	The ethical challenges of in utero gene therapy. Nature Genetics, 2000, 24, 107-107.	21.4	15
445	A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Therapy, 2000, 7, 1511-1518.	4.6	48
446	Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Therapy, 2000, 7, 1761-1767.	4.5	34
447	Electron Microscopic Evaluation of Vector Quality for Gene Therapy. Microscopy and Microanalysis, 2000, 6, 858-859.	0.4	0
448	Intravenous Injection of an Adenovirus Encoding Hepatocyte Growth Factor Results in Liver Growth and Has a Protective Effect Against Apoptosis. Molecular Medicine, 2000, 6, 96-103.	4.4	43
449	CD40 Ligand-Dependent Activation of Cytotoxic T Lymphocytes by Adeno-Associated Virus Vectors In Vivo: Role of Immature Dendritic Cells. Journal of Virology, 2000, 74, 8003-8010.	3.4	110
450	Th2-Dependent B Cell Responses in the Absence of CD40-CD40 Ligand Interactions. Journal of Immunology, 2000, 164, 248-255.	0.8	18

#	Article	IF	Citations
451	Rescue of Skeletal Muscles of Î³-Sarcoglycan- Deficient Mice with Adeno-Associated Virus-Mediated Gene Transfer. Molecular Therapy, 2000, 1, 119-129.	8.2	91
452	A Quantitative Nonimmunogenic Transgene Product for Evaluating Vectors in Nonhuman Primates. Molecular Therapy, 2000, 2, 657-659.	8.2	7
453	Route of Administration Determines Induction of T-Cell-Independent Humoral Responses to Adeno-Associated Virus Vectors. Molecular Therapy, 2000, 1, 323-329.	8.2	108
454	Adeno-Associated Virus Mediates Long-Term Gene Transfer and Delivery of Chondroprotective IL-4 to Murine Synovium. Molecular Therapy, 2000, 2, 147-152.	8.2	96
455	A Cell Line for High-Yield Production of E1-Deleted Adenovirus Vectors without the Emergence of Replication-Competent Virus. Human Gene Therapy, 2000, 11, 213-219.	2.7	34
456	In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral Vectors. Molecular Therapy, 2000, 1, 414-422.	8.2	36
457	Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and Its Performancein Vivo. Human Gene Therapy, 2000, 11, 2079-2091.	2.7	176
458	Readministration of Adenovirus Vector in Nonhuman Primate Lungs by Blockade of CD40-CD40 Ligand Interactions. Journal of Virology, 2000, 74, 3345-3352.	3.4	59
459	Bacterial Phosphorylcholine Decreases Susceptibility to the Antimicrobial Peptide LL-37/hCAP18 Expressed in the Upper Respiratory Tract. Infection and Immunity, 2000, 68, 1664-1671.	2.2	173
460	Combination Therapy with Lamivudine and Adenovirus Causes Transient Suppression of Chronic Woodchuck Hepatitis Virus Infections. Journal of Virology, 2000, 74, 11754-11763.	3.4	35
461	Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle. Journal of Virology, 2000, 74, 2420-2425.	3.4	174
462	Development of a Rapid Method for the PEGylation of Adenoviruses with Enhanced Transduction and Improved Stability under Harsh Storage Conditions. Human Gene Therapy, 2000, 11, 1713-1722.	2.7	133
463	Prolonged Correction of Hyperlipidemia in Mice with Familial Hypercholesterolemia Using an Adeno-Associated Viral Vector Expressing Very-Low-Density Lipoprotein Receptor. Molecular Therapy, 2000, 2, 256-261.	8.2	63
464	Efficient Mitochondrial Import of Newly Synthesized Ornithine Transcarbamylase (OTC) and Correction of Secondary Metabolic Alterations in spfash Mice following Gene Therapy of OTC Deficiency. Molecular Medicine, 1999, 5, 244-253.	4.4	9
465	Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide. Infection and Immunity, 1999, 67, 6084-6089.	2.2	268
466	Adenoviral RB2/p130 Gene Transfer Inhibits Smooth Muscle Cell Proliferation and Prevents Restenosis After Angioplasty. Circulation Research, 1999, 85, 1032-1039.	4.5	63
467	bcl-2 Gene Therapy Exacerbates Excitotoxicity. Human Gene Therapy, 1999, 10, 1715-1720.	2.7	18
468	Recombinant Adenovirus Gene Transfer in Adults with Partial Ornithine Transcarbamylase Deficiency (OTCD). Human Gene Therapy, 1999, 10, 2419-2437.	2.7	42

#	Article	IF	Citations
469	Evaluation of an E1E4-Deleted Adenovirus Expressing the Herpes Simplex Thymidine Kinase Suicide Gene in Cancer Gene Therapy. Human Gene Therapy, 1999, 10, 463-475.	2.7	31
470	Fas-Fas Ligand Interactions Play a Major Role in Effector Functions of Cytotoxic T Lymphocytes after Adenovirus Vector-Mediated Gene Transfer. Human Gene Therapy, 1999, 10, 259-269.	2.7	34
471	A Phase I Study of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to a Lung Segment of Individuals with Cystic Fibrosis. Human Gene Therapy, 1999, 10, 2973-2985.	2.7	138
472	Adenoviral Vector-Mediated Gene Therapy in the Mouse Lung: No Role of Fas-Fas Ligand Interactions for Elimination of Transgene Expression in Bronchioepithelial Cells. Human Gene Therapy, 1999, 10, 2839-2846.	2.7	9
473	Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8657-8662.	7.1	177
474	Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9920-9925.	7.1	226
475	Constitutive and Regulated Expression in the Systemic Delivery of Erythropoietin Following Skeletal Muscle Transduction with DNA Viral Vectors. Nature Biotechnology, 1999, 17, 13-13.	17.5	0
476	Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nature Medicine, 1999, 5, 439-443.	30.7	207
477	Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy, 1999, 6, 1574-1583.	4.5	655
478	Regulated Delivery of Therapeutic Proteins After in Vivo Somatic Cell Gene Transfer. Science, 1999, 283, 88-91.	12.6	313
479	Gene Transfer into the Liver of Nonhuman Primates with E1-Deleted Recombinant Adenoviral Vectors: Safety of Readministration. Human Gene Therapy, 1999, 10, 2515-2526.	2.7	119
480	Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Research, 1999, 39, 2545-2553.	1.4	149
481	Fetal gene therapy: Efficacy, toxicity, and immunologic effects of early gestation recombinant adenovirus. Journal of Pediatric Surgery, 1999, 34, 235-241.	1.6	44
482	Sustained Production of Î²-Glucuronidase from Localized Sites after AAV Vector Gene Transfer Results in Widespread Distribution of Enzyme and Reversal of Lysosomal Storage Lesions in a Large Volume of Brain in Mucopolysaccharidosis VII Mice. Experimental Neurology, 1999, 160, 17-27.	4.1	135
483	Mouse Î²-Defensin 3 Is an Inducible Antimicrobial Peptide Expressed in the Epithelia of Multiple Organs. Infection and Immunity, 1999, 67, 3542-3547.	2.2	172
484	Overexpression of Cyclin A Inhibits Augmentation of Recombinant Adeno-Associated Virus Transduction by the Adenovirus E4orf6 Protein. Journal of Virology, 1999, 73, 10010-10019.	3.4	24
485	Gene Therapy Vectors Based on Adeno-Associated Virus Type 1. Journal of Virology, 1999, 73, 3994-4003.	3.4	484
486	Transduction of Well-Differentiated Airway Epithelium by Recombinant Adeno-Associated Virus Is Limited by Vector Entry. Journal of Virology, 1999, 73, 6085-6088.	3.4	69

#	Article	IF	Citations
487	The innate immune system in cystic fibrosis lung disease. Journal of Clinical Investigation, 1999, 103, 303-307.	8.2	184
488	Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. Journal of Clinical Investigation, 1999, 103, 1113-1117.	8.2	172
489	Correction of Ureagenesis after Gene Transfer in an Animal Model and after Liver Transplantation in Humans with Ornithine Transcarbamylase Deficiency. Pediatric Research, 1999, 46, 588-588.	2.3	19
490	Adeno-Associated Virus(AAV)-Mediated Expression of Ornithine Transcarbamylase (OTC) in OTC Deficient spf-ash mMice. Pediatric Research, 1999, 45, 142A-142A.	2.3	0
491	In vivo measurement of ureagenesis with stable isotopes. Journal of Inherited Metabolic Disease, 1998, 21, 21-29.	3.6	18
492	Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. Journal of Inherited Metabolic Disease, 1998, 21, 119-137.	3.6	38
493	Fas ligandâ€"a double-edged sword. Nature Biotechnology, 1998, 16, 1011-1012.	17.5	122
494	Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy, 1998, 5, 309-319.	4.5	131
495	High throughput method for creating and screening recombinant adenoviruses. Gene Therapy, 1998, 5, 1148-1152.	4.5	45
496	Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine, 1998, 16, 1812-1817.	3.8	39
497	METHODS OF GENE DELIVERY. Hematology/Oncology Clinics of North America, 1998, 12, 483-501.	2.2	80
498	High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus. Human Gene Therapy, 1998, 9, 2353-2362.	2.7	186
499	Selective Gene Transfer into the Liver of Non-Human Primates with E1-Deleted, E2A-Defective, or E1-E4 Deleted Recombinant Adenoviruses. Human Gene Therapy, 1998, 9, 671-679.	2.7	44
500	Evaluating the Potential of Germ Line Transmission after Intravenous Administration of Recombinant Adenovirus in the C3H Mouse. Human Gene Therapy, 1998, 9, 2135-2142.	2.7	62
501	Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma. Human Gene Therapy, 1998, 9, 2121-2133.	2.7	196
502	Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma. Human Gene Therapy, 1998, 9, 1083-1092.	2.7	328
503	Interferon-Î² gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14411-14416.	7.1	129
504	The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9541-9546.	7.1	658

#	Article	IF	Citations
505	Mouse Î²-Defensin 1 Is a Salt-Sensitive Antimicrobial Peptide Present in Epithelia of the Lung and Urogenital Tract. Infection and Immunity, 1998, 66, 1225-1232.	2.2	172
506	Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy. Journal of Virology, 1998, 72, 10222-10226.	3.4	152
507	Cytotoxic T-Lymphocyte Target Proteins and Their Major Histocompatibility Complex Class I Restriction in Response to Adenovirus Vectors Delivered to Mouse Liver. Journal of Virology, 1998, 72, 2945-2954.	3.4	115
508	Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers. Journal of Virology, 1998, 72, 4212-4223.	3.4	419
509	Role of E4 in Eliciting CD4 T-Cell and B-Cell Responses to Adenovirus Vectors Delivered to Murine and Nonhuman Primate Lungs. Journal of Virology, 1998, 72, 6138-6145.	3.4	70
510	Lentiviral Vectors for Gene Therapy of Cystic Fibrosis. Human Gene Therapy, 1997, 8, 2261-2268.	2.7	114
511	Adenovirus-Mediated Gene Transfer by Perivitelline Microinjection of Mouse, Rat, and Cow Embryos1. Biology of Reproduction, 1997, 56, 119-124.	2.7	21
512	Intracranial Administration of Adenovirus Expressing HSV-TK in Combination with Ganciclovir Produces a Dose-Dependent, Self-Limiting Inflammatory Response. Human Gene Therapy, 1997, 8, 943-954.	2.7	61
513	The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. Biochemical Journal, 1997, 321, 49-58.	3.7	56
514	Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5804-5809.	7.1	480
515	Human Î²-Defensin-1 Is a Salt-Sensitive Antibiotic in Lung That Is Inactivated in Cystic Fibrosis. Cell, 1997, 88, 553-560.	28.9	1,059
516	Making space for intestinal gene therapy. Gastroenterology, 1997, 112, 1753-1756.	1.3	4
517	Recombinant adeno-associated virus for muscle directed gene therapy. Nature Medicine, 1997, 3, 306-312.	30.7	661
518	Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.. Journal of Clinical Investigation, 1997, 100, 1951-1957.	8.2	182
519	Adenovirus-Mediated in Vivo Gene Transfer Rapidly Protects Ornithine Transcarbamylase-Deficient Mice from an Ammonium Challenge. Pediatric Research, 1997, 41, 527-534.	2.3	30
520	Gene transfer by adenovirus in smooth muscle cells. Respiration Physiology, 1996, 105, 155-162.	2.7	3
521	Adenoviruses as Gene-Delivery Vehicles. New England Journal of Medicine, 1996, 334, 1185-1187.	27.0	460
522	A Novel Adenovirusâ€"Adeno-Associated Virus Hybrid Vector That Displays Efficient Rescue and Delivery of the AAV Genome. Human Gene Therapy, 1996, 7, 2079-2087.	2.7	102

#	Article	IF	Citations
523	CD40 Ligand-Dependent T Cell Activation: Requirement of B7-CD28 Signaling Through CD40. Science, 1996, 273, 1862-1864.	12.6	391
524	Safety of Intrapleurally Administered Recombinant Adenovirus Carrying Herpes Simplex Thymidine Kinase DNA Followed by Ganciclovir Therapy in Nonhuman Primates. Human Gene Therapy, 1996, 7, 2225-2233.	2.7	40
525	Treatment of Advanced CNS Malignancies with the Recombinant Adenovirus H5.010RSVTK: A Phase I Trial. University of Pennsylvania Medical Center, Philadelphia. Human Gene Therapy, 1996, 7, 1465-1482.	2.7	110
526	Targeted retroviral gene transfer into the rat biliary tract. Somatic Cell and Molecular Genetics, 1996, 22, 21-29.	0.7	8
527	Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis. Virology, 1996, 217, 11-22.	2.4	308
528	A Replication-Defective Human Adenovirus Recombinant Serves as a Highly Efficacious Vaccine Carrier. Virology, 1996, 219, 220-227.	2.4	243
529	Round two for liver gene therapy. Nature Genetics, 1996, 12, 232-233.	21.4	24
530	Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirusâ€“mediated transfer of the VLDL receptor gene. Nature Genetics, 1996, 13, 54-62.	21.4	175
531	A pharmacologenic rheostat for gene therapy. Nature Medicine, 1996, 2, 977-978.	30.7	6
532	Prolonged Metabolic Correction in Adult Ornithine Transcarbamylase-deficient Mice with Adenoviral Vectors. Journal of Biological Chemistry, 1996, 271, 3639-3646.	3.4	146
533	Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Human Molecular Genetics, 1996, 5, 1703-1712.	2.9	149
534	Cyclophosphamide Diminishes Inflammation and Prolongs Transgene Expression Following Delivery of Adenoviral Vectors to Mouse Liver and Lung. Human Gene Therapy, 1996, 7, 1555-1566.	2.7	166
535	In Vivo Expression of Full-Length Human Dystrophin from Adenoviral Vectors Deleted of All Viral Genes. Human Gene Therapy, 1996, 7, 1907-1914.	2.7	153
536	Treatment of Advanced Mesothelioma with the Recombinant Adenovirus H5.010RSVTK: A Phase 1 Trial (BB-IND 6274). Human Gene Therapy, 1996, 7, 2047-2057.	2.7	32
537	Hepatic Expression of the Catalytic Subunit of the Apolipoprotein B mRNA Editing Enzyme (apobec-1) Ameliorates Hypercholesterolemia in LDL Receptor-Deficient Rabbits. Human Gene Therapy, 1996, 7, 943-957.	2.7	62
538	Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia. Annals of Surgery, 1996, 223, 116-126.	4.2	99
539	Animal models of human disease for gene therapy.. Journal of Clinical Investigation, 1996, 97, 1138-1141.	8.2	18
540	When bad gene transfer is good.. Journal of Clinical Investigation, 1996, 98, 2435-2435.	8.2	2

#	Article	IF	Citations
541	Treatment of Experimental Human Mesothelioma Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase Gene. Annals of Surgery, 1995, 222, 78-86.	4.2	100
542	Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7257-7261.	7.1	270
543	Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nature Genetics, 1995, 9, 126-131.	21.4	97
544	Recombinant ILâ€“12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Medicine, 1995, 1, 890-893.	30.7	262
545	A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Medicine, 1995, 1, 1148-1154.	30.7	515
546	Characterization of stem cells in human airway capable of reconstituting a fully differentiated bronchial epithelium. Somatic Cell and Molecular Genetics, 1995, 21, 61-73.	0.7	35
547	Adenovirus-mediated gene transfer to liver. Advanced Drug Delivery Reviews, 1995, 17, 303-307.	13.7	21
548	Gene therapy of hypercholesterolemic disorders. Trends in Cardiovascular Medicine, 1995, 5, 205-209.	4.9	4
549	Prospects for gene therapy in ornithine carbamoyltransferase deficiency and other urea cycle disorders. Mental Retardation and Developmental Disabilities Research Reviews, 1995, 1, 62-70.	3.6	4
550	The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.. Journal of Clinical Investigation, 1995, 95, 1403-1408.	8.2	177
551	A Controlled Study of Adenoviral-Vectorâ€“Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis. New England Journal of Medicine, 1995, 333, 823-831.	27.0	591
552	Gene transfer to primate liver using second generation recombinant adenovirus. Gastroenterology, 1995, 108, A1135.	1.3	0
553	Transfer of the CFTR Gene to the Lung of Nonhuman Primates with E1-Deleted, E2a-Defective Recombinant Adenoviruses: A Preclinical Toxicology Study. Human Gene Therapy, 1995, 6, 839-851.	2.7	92
554	Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. Journal of Virology, 1995, 69, 5951-5958.	3.4	175
555	Gene therapy for cystic fibrosis: challenges and future directions.. Journal of Clinical Investigation, 1995, 96, 2547-2554.	8.2	81
556	Gene Therapy of Cystic Fibrosis Lung Disease Using E1 Deleted Adenoviruses: A Phase I Trial. University of Michigan, Ann Arbor, Michigan and University of Pennsylvania, Philadelphia, Pennsylvania. Human Gene Therapy, 1994, 5, 501-519.	2.7	87
557	Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2a. Human Gene Therapy, 1994, 5, 1217-1229.	2.7	232
558	Gene Therapy for Cystic Fibrosis Using E1-Deleted Adenovirus: A Phase I Trial in the Nasal Cavity. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Human Gene Therapy, 1994, 5, 615-639.	2.7	113

#	Article	IF	Citations
559	Cystic Fibrosis: Strategies for Gene Therapy. Seminars in Respiratory and Critical Care Medicine, 1994, 15, 439-445.	2.1	8
560	Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genetics, 1994, 6, 335-341.	21.4	577
561	Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genetics, 1994, 7, 362-369.	21.4	511
562	Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature, 1994, 371, 802-806.	27.8	381
563	Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Annals of Thoracic Surgery, 1994, 57, 1395-1401.	1.3	124
564	MHC class I-cestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity, 1994, 1, 433-442.	14.3	648
565	Biochemical and functional analysis of an adenovirus-based ligand complex for gene transfer. Biochemical Journal, 1994, 299, 49-58.	3.7	45
566	Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4407-4411.	7.1	1,594
567	Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 6196-6200.	7.1	633
568	Expression of the cystic fibrosis gene in adult human lung.. Journal of Clinical Investigation, 1994, 93, 737-749.	8.2	234
569	Vehicles for gene therapy. Nature, 1993, 365, 691-692.	27.8	49
570	A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genetics, 1993, 3, 219-223.	21.4	609
571	Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1â€“deleted adenoviruses. Nature Genetics, 1993, 4, 27-34.	21.4	317
572	Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somatic Cell and Molecular Genetics, 1993, 19, 449-458.	0.7	84
573	Therapeutic strategies for familial hypercholesterolemia based on somatic gene transfer. American Journal of Cardiology, 1993, 72, D59-D63.	1.6	8
574	Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. Human Molecular Genetics, 1993, 2, 1253-1261.	2.9	83
575	Retroviruses: delivery vehicle to the liver. Current Opinion in Genetics and Development, 1993, 3, 110-114.	3.3	24
576	Gene therapy: adenovirus vectors. Current Opinion in Genetics and Development, 1993, 3, 499-503.	3.3	421

#	Article	IF	Citations
577	Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Toxicity Study. Human Gene Therapy, 1993, 4, 771-780.	2.7	338
578	An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4601-4605.	7.1	140
579	Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Biological Efficacy Study. Human Gene Therapy, 1993, 4, 759-769.	2.7	225
580	Expression of an abundant alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. Human Molecular Genetics, 1993, 2, 225-230.	2.9	100
581	The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9480-9484.	7.1	332
582	Cell Transplantation in Liver-Directed Gene Therapy. Cell Transplantation, 1993, 2, 381-400.	2.5	46
583	Adenoviral-mediated gene transfer to rabbit synovium in vivo.. Journal of Clinical Investigation, 1993, 92, 1085-1092.	8.2	174
584	Hepatocyte Transplantation: Development of New Systems for Liver Repopulation and Gene Therapy. Seminars in Liver Disease, 1992, 12, 321-331.	3.6	24
585	Ex Vivo Gene Therapy of Familial Hypercholesterolemia. Howard Hughes Medical Institute, University of Michigan. Human Gene Therapy, 1992, 3, 179-222.	2.7	97
586	Transplantation of Genetically Modified Autologous Hepatocytes into Nonhuman Primates: Feasibility and Short-Term Toxicity. Human Gene Therapy, 1992, 3, 501-510.	2.7	89
587	Role of CFTR in lysosome acidification. Biochemical and Biophysical Research Communications, 1992, 184, 300-305.	2.1	23
588	A welcome animal model. Nature, 1992, 358, 708-709.	27.8	16
589	More from the modellers. Nature, 1992, 359, 195-196.	27.8	13
590	Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic mice. Nature Genetics, 1992, 2, 13-20.	21.4	89
591	Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nature Genetics, 1992, 2, 240-248.	21.4	649
592	Targeted delivery of antisense oligonucleotides by molecular conjugates. Somatic Cell and Molecular Genetics, 1992, 18, 559-569.	0.7	54
593	Provocative gene therapy strategy for the treatment of hepatocellular carcinoma. Hepatology, 1992, 16, 273-274.	7.3	7
594	In vivo retroviral gene transfer into human bronchial epithelia of xenografts.. Journal of Clinical Investigation, 1992, 90, 2598-2607.	8.2	81

#	Article	IF	Citations
595	Somatic gene transfer in the development of an animal model for primary hyperparathyroidism. Endocrinology, 1992, 130, 2947-2954.	2.8	2
596	Expression of Retroviral Transduced Human CD18 in Murine Cells: AnIn VitroModel of Gene Therapy for Leukocyte Adhesion Deficiency. Human Gene Therapy, 1991, 2, 221-228.	2.7	17
597	Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8101-8105.	7.1	124
598	Towards liver-directed gene therapy: Retrovirus-mediated gene transfer into human hepatocytes. Somatic Cell and Molecular Genetics, 1991, 17, 601-607.	0.7	30
599	Expression of human adenosine deaminase in mice reconstituted with retrovirus-transduced hematopoietic stem cells.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 439-443.	7.1	105
600	Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8437-8441.	7.1	123
601	Correction of CD18-deficient lymphocytes by retrovirus-mediated gene transfer. Science, 1990, 248, 1413-1416.	12.6	61
602	Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell, 1990, 62, 1227-1233.	28.9	595
603	Implantation of vascular grafts lined with genetically modified endothelial cells. Science, 1989, 244, 1344-1346.	12.6	343
604	Retrovirus-mediated transduction of adult hepatocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3014-3018.	7.1	148
605	Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4421-4425.	7.1	150
606	Hypoxanthine-guanine phosphoribosyltransferase. Genetic evidence for identical mutations in two partially deficient subjects.. Journal of Clinical Investigation, 1988, 82, 2164-2167.	8.2	23
607	A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man.. Journal of Clinical Investigation, 1986, 77, 188-195.	8.2	97
608	Molecular genetics of hypoxanthine-guanine phosphoribosyltransferase deficiency in man. Archives of Internal Medicine, 1985, 145, 1895-1900.	3.8	2
609	Genetic Mechanism(S) Responsible for a Deficiency of Adenine Phosphoribosyltransferase in Man. Advances in Experimental Medicine and Biology, 1984, 165 Pt A, 385-389.	1.6	1
610	The Primary Structure and Posttranslational Modification of Human Hypoxanthine-Guanine Phosphoribosyltransferase. Advances in Experimental Medicine and Biology, 1984, 165 Pt B, 39-44.	1.6	0
611	Human adenine phosphoribosyltransferase: Characterization from subjects with a deficiency of enzyme activity. Biochemical Genetics, 1983, 21, 1121-1134.	1.7	9
612	Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency. New England Journal of Medicine, 1983, 309, 900-910.	27.0	128

#	Article	IF	Citations
613	Human hypoxanthine (guanine) phosphoribosyltransferase: an amino acid substitution in a mutant form of the enzyme isolated from a patient with gout.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 870-873.	7.1	66
614	Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in a patient with the Lesch-Nyhan syndrome.. Journal of Clinical Investigation, 1983, 71, 1331-1335.	8.2	47
615	Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.. Journal of Clinical Investigation, 1983, 72, 483-492.	8.2	43
616	Human hypoxanthine-guanine phosphoribosyltransferase. Detection of a mutant allele by restriction endonuclease analysis.. Journal of Clinical Investigation, 1983, 72, 767-772.	8.2	23
617	Human hypoxanthine-guanine phosphoribosyltransferase. Demonstration of structural variants in lymphoblastoid cells derived from patients with a deficiency of the enzyme.. Journal of Clinical Investigation, 1982, 69, 706-715.	8.2	69
618	Are Health Education Conferences Effective? An Evaluation of Knowledge Gain in a Three-Day Institute. Health Education, 1981, 12, 22-24.	0.1	5
619	Molecular Mechanism(s) of Deoxyribonucleoside Toxicity in T-Lymphoblasts. Advances in Experimental Medicine and Biology, 1980, 122B, 265-270.	1.6	1
620	Defective transport and other phenotypes of a periplasmic "leaky" mutant of Escherichia coli K-12. Journal of Bacteriology, 1979, 140, 351-358.	2.2	31
621	Purinogenic Immunodeficiency Diseases. Journal of Clinical Investigation, 1979, 64, 1475-1484.	8.2	48
622	Vector Sequences Are Not Detected In Tumor Tissue From Research Subjects With Ornithine Transcarbamylase Deficiency Who Previously Received Adenovirus Gene Transfer. Human Gene Therapy, 0, , 130827105058001.	2.7	0
623	Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors. Human Gene Therapy Methods, 0, , .	2.1	2